The Burden of Proof Belongs to Us
Why we certified Keikku’s Scribe as a CE MDR Class I medical device, and why the burden of proof belongs to the builder, not the clinician.
A few days ago we wrote about a new kind of burnout spreading through medicine. Not the burnout of long shifts and heavy patient loads, familiar as those are, but a quieter one. The exhaustion of clinicians feeling they must personally verify a technology they were never trained to verify. Reading about large language models between shifts. Auditing algorithms they never signed up to audit. Becoming, each of them, their own regulatory agency because no one else had taken on the job.
The argument was simple. In medicine, the burden of proof is supposed to sit with the builder, not the user. Manufacturers prove. Regulators verify. Clinicians apply. That is the pattern that made drugs and devices trustworthy, and it is the pattern clinical AI arrived without. When a tool shows up unvalidated, the weight of trust falls on the person with the least time to carry it.
Today we want to do more than make the argument. We want to report that we have taken on the burden ourselves.
Keikku's Scribe is now a CE MDR Class I medical device
Keikku's Scribe, the ambient documentation core of our platform, is now certified as a Class I medical device under the European Union Medical Device Regulation.
Under MDR obligations, software intended for a medical purpose is a medical device, and it must be classified, evaluated, documented, and held to the standards of one before it reaches a patient. The EU MDR is widely regarded as the most rigorous medical device framework in the world. Certification means the vetting was done before the tool arrived at the bedside, by the manufacturer and against an external standard, so the clinician does not have to build trust from scratch.
We chose this deliberately, here is why. This European framework is not required in the United States, where we are also scaling. However, we believe the US market can use this proof for trust, at a time when so many products in the market remain unregulated. Our point has never been to meet the minimum standard. Our view is to build from a position of trust, and the way to do that is to remove a question from the clinician's plate. Every certification we carry is a question a clinician does not have to ask.
What this means for Keikku
There is a larger picture behind today's news.
Lapsi Health now holds regulatory approval on two continents, across two different kinds of technology. In Europe, our generative AI software, the Keikku Scribe, is a CE MDR Class I medical device. In the United States, our hardware, the Keikku device, is FDA cleared. Regulated AI software in one market. A cleared medical device in the other. Both under our name.
We believe this makes Lapsi the first generative AI company to hold regulatory approvals spanning both generative AI software and a proper hardware medical device, across both Europe and the United States.
This is not a trophy. This is proof of our commitment to trust above everything else. For a company, it is easy to claim credibility by requesting trust with no proof. It is harder, slower, and more meaningful to actually carry the burden of proof through multiple regulatory systems. We chose the second path deliberately.
The future we are building toward
The future of clinical AI is not a generation of doctors who moonlight as machine learning engineers. It is a generation of clinicians who can apply trusted tools, built by technologists (and also clinicians) who carried the burden of proof.
That world does not build itself. It is built one certification, one evaluation, one honest regulatory pathway at a time.